ALPARSLAN ERSOY, Canan ERSOY, Muge GULER EREK, Abdülmecit YILDIZ

Losartan and QT Dispersion in Hypertensive Patients on Maintenance Hemodialysis

QT and corrected QT (QTc) intervals and their increased dispersions (QTd, QTcd) have been linked to the occurrence of arrhythmias in hemodialysis (HD) patients. This study was performed to determine the effects of the angiotensin II receptor blocker losartan on these parameters in HD patients. Our cohort comprised 24 dialysis patients and 14 healthy controls. 15 dialysis patients were treated for 16 weeks with losartan (HD losartan group) but not 9 patients (HD control group). Blood pressures (BP) and electrocardiogram-derived data (Sokolow-Lyon and Cornell voltages, QT, QTd, QTc and QTcd) were measured in all patients. At the beginning of the study, there were no differences in patient characteristics among the 3 groups. Baseline maximum QTc, QTd, QTcd and Socolow-Lyon and Cornell voltages and BPs of the healthy group were lower than those of HD groups. While these parameters were similar in the dialysis groups, only BPs in losartan group were higher. After 16 weeks, BPs, Socolow-Lyon and Cornell voltages values in losartan group significantly decreased but not in the HD control group. Whereas maximum QT and QTc, QTd, QTcd, heart rate and QRS interval did not change in the HD groups. Electrocardiographic LVH of 2 patients improved in the losartan group. Losartan reduced BP and electrocardiographic LVH was improved in HD patients without affecting QTd and QTcd during the 16-week study period.

PDF

___

1. Guerin AP, Pannier B, Marchais SJ, London GM. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens. 2006;15(2):105-10.

2. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004;19(5):1058-68.

3. Zazgornik J, Biesenbach G, Forstenlehner M, Stummvoll K. Profile of antihypertensive drugs in hypertensive pa tients on renal replacement therapy (RRT). Clin Nephrol. 1997;48(6):337-40.

4. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153.

5. Toto R1, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension. 1998;31(2):684-91.

6. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl. 1998;68:S125-129.

7. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52(3):501-6.

8. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350-7.

9. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med. 2010;363(19):1833-45.

10. Wang CL, Lee WL, Wu MJ, Cheng CH, Chen CH, Shu KH. Increased QTc dispersion and mortality in uremic patients with acute myocardial infarction. Am J Kidney Dis. 2002;39(3):539-48.

11. Saadeh A, Evans S, James M, Jones J. QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients. J Hum Hypertens. 1999;13(10):665-9.

12. Oktavia D, Nasution SA, Setiati S. The clinical factors' prediction of increased intradialytic QT dispersion on the electrocardiograms of chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2013;24(2):274-80.

13. Lorincz I, Matyus J, Zilahi Z, Kun C, Karanyi Z, Kakuk G. QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol. 1999;10(6):1297-302.

14. Morris ST, Galiatsou E, Stewart GA, Rodger RS, Jardine AG. QT dispersion before and after hemodialysis. J Am Soc Nephrol. 1999;10(1):160-163.

15. Brooksby P, Robinson PJ, Segal R, Klinger G, Pitt B, Cowley AJ. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. Lancet. 1999;354(9176):395-6.

16. Thomas GP, Ferrier GR, Howlett SE. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther. 1996;278(3):1090-7.

17. Averbukh Z, Berman S, Efrati S, Manevits E, Rosenberg R, Malcev E, Galperin E, Weissgarten J. Blockade of renin-angiotensin system reduces QT dispersion and improves intracellular Ca/Mg status in hemodialysis patients. Nephron Clin Pract. 2006;104(4):c176-184.

18. Bonomini MP, Arini PD, Gonzalez GE, Buchholz B, Valentinuzzi ME. The allometric model in chronic myocardial infarction. Theor Biol Med Model. 2012;9:15.

19. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. 1949. Ann Noninvasive Electrocardiol. 2001;6(4):343-68.

20. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75(3):565-

21. Jardine AG, McLaughlin K. Cardiovascular complications of renal disease. Heart. 2001;86(4):459-66.

22. Zuber M, Steinmann E, Huser B, Ritz R, Thiel G, Brunner F. Incidence of arrhythmias and myocardial ischaemia during haemodialysis and haemofiltration. Nephrol Dial Transplant. 1989;4(7):632-4.

23. Covic A, Diaconita M, Gusbeth-Tatomir P, et al. Haemodialysis increases QT(c) interval but not QT(c) dispersion in ESRD patients without manifest cardiac disease. Nephrol Dial Transplant. 2002;17(12):2170-7.

24. Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ. Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis. 2002;39(4):834-42.

25. Familoni OB, Alebiosu CO, Ayodele OE. Effects and outcome of haemodialysis on QT intervals and QT dispersion in patients with chronic kidney disease. Cardiovasc J S Afr. 2006;17(1):19-23.

26. Nakamura S, Ogata C, Aihara N, Sasaki O, Yoshihara F, Nakahama H, Inenaga T, Kimura G, Kawano Y. QTc dispersion in haemodialysis patients with cardiac complications. Nephrology (Carlton). 2005;10(2):113-8.

27. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol. 2000;36(6):1749-1766.

28. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002;40(5):1023-9.

29. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol. 2002;90(10):1107-12.

30. Barr CS, Naas AA, Fenwick M, Struthers AD. Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1997;79(3):328-33.

31. Gang Y, Ono T, Hnatkova K, Hashimoto K, Camm AJ, Pitt B, Poole-Wilson PA, Malik M; ELITE II investigators. QT dispersion has no prognostic value in patients with symptomatic heart failure: an ELITE II substudy. Pacing Clin Electrophysiol. 2003;26(1 Pt 2):394-400.

32. Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, et al. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol. 1998;81(2):170-4.

33. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, Toutouzas PK. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J. 1998;136(5):765-8.

34. Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM; LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic

35. Caballero R, Delpon E, Valenzuela C, Longobardo M, Tamargo J. Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents. Circulation. 2000;101(10):1199-205.

36. Lynch JJ, Jr., Stump GL, Wallace AA, Painter CA, Thomas JM, Kusma SE, Gould RJ, Grossman W. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. J Am Coll Cardiol. 1999;34(3):876-84.

37. Porthan K, Viitasalo M, Hiltunen TP, Vaananen H, Dabek J, Suonsyrja T, HannilaHandelberg T, Virolainen J, Nieminen MS, Toivonen L, Kontula K, Oikarinen L. Shortterm electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Ann Med. 2009;41(1):29-37.

38. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Carpi A, Antonelli A, Santoro G. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother. 2010;64(8):516-20.

39. Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res. 2007;30(4):307-13.